Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: Clinical implications

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2468-2477

  Kwiatkowski, David J ^a   Harpole Jr , David H ^b   Godleski, John ^b   Herndon II, James E ^b   Shieh, Dar Bin ^b   Richards, William ^b   Blanco, Rwamon ^b   Xu, Hong Ji ^b   Strauss, Gary M ^b   Sugarbaker, David J ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SENESCENCE; SEX DIFFERENCE; SURGICAL TECHNIQUE; TUMOR VOLUME;

EID: 20244388951     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2468     Document Type: Article

References (34)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics - 1996. CA Cancer J Clin 47:5-27, 1997
2. Fry WA, Menck HR, Winchester DP: The National Cancer Data Base report on lung cancer. Cancer 77:1947-1955, 1996
3. Bulzebruck H, Bopp R, Drings P, et al: New aspects of staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 70:1102-1110, 1992
4. Strauss GM, Kwiatkowski DJ, Harpole DH, et al: Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 13:1265-1279, 1995
5. Strauss GM: Prognostic markers in resectable non-small-cell carcinoma of the lung. Hematol Oncol Clin North Am 11:409-434, 1997
6. Harpole DH, Herndon JE, Wolfe WG, et al: A prognostic model of recurrence and death in stage I non-small-cell lung cancer utilizing presenting symptoms, histopathology and oncoprotein staining. Cancer Res 55:51-56, 1995
7. Harpole DH, Richards WG, Herndon JE, et al: Angiogenesis and molecular biologic substaging in patients with stage I non-small-cell lung cancer. Ann Thorac Surg 61:1470-1476, 1996
8. Graziano SL, Tatum AH, Newman NB, et al: The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small-cell lung cancer. Cancer Res 54:2908-2913, 1994
9. Pastorino U, Andreola S, Tagliabue E, et al: Immunocytochemical markers in stage I lung cancer: Relevance to prognosis. J Clin Oncol 15:2858-2865, 1997
10. Kreyberg L: Lung tumors. J Clin Pathol 24:766-767, 1971
11. Tateishi M, Ishida T, Mitsudomi T, et al: Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27:1372-1375, 1991
12. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184-5191, 1990
13. Harada M, Dosaka-Akita H, Miyamoto H, et al: Prognostic significance of the expression of ras oncogene product in non-small-cell lung cancer. Cancer 69:72-77, 1992
14. Miyamoto H, Harada M, Isobe H, et al: Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer research. Cancer 51:6346-6350, 1991
15. Xu HJ, Quinlan DC, Davidson AG, et al: Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst 86:695-699, 1994
16. Pezzella F, Turley H, Kuzu I, et al: bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690-694, 1993
17. Quinlan DC, Davidson AG, Summers CL, et al: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828-4831, 1992
18. Carbone DP, Mitsudomi T, Chiba I, et al: P53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small-cell lung cancer. Chest 106:3775-3818, 1994
19. Lee JS, Ro JY, Sahin AA, et al: Expression of blood-group antigen A - A favorable prognostic factor in non-small-cell lung cancer. N Engl J Med 324:1084-1090, 1991
20. b antigens with survival in patients with carcinoma of the lung. N Engl J Med 327:14-18, 1992
21. Jiang W, Kahn SM, Guillem JG, et al: Rapid detection of ras oncogenes in human tumors: Applications to colon, esophageal, and gastric cancer. Oncogene 4:923-928, 1989
22. Kumar R, Dunn LL: Designed diagnostic restriction fragment length polymorphisms for the detection of point mutations in ras oncogenes. Oncogene Res 4:235-241, 1989
23. Graziano SL: Non-small-cell lung cancer: Clinical value of new biological predictors. Lung Cancer 17:S37-S58, 1997
24. Martini N, Bains MS, Burt ME, et al: Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109:120-129, 1995
25. Ginsberg RJ, Rubinstein LV: Randomized trial of lobectomy versus limited resection for T1NO non-small-cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615-622, 1995
26. Harpole DH, Herndon JE, Young WG, et al: Stage I non-small-cell lung cancer: A multivariate analysis of treatment methods and patterns of recurrence. Cancer 76:787-796, 1995
27. Sorensen JB, Badsberg JH: Prognostic factors in resected stage I and II adenocarcinoma of the lung. J Thorac Cardiovasc Surg 50:218-226, 1990
28. Shields TW: Prognostic significance of parenchymal lymphatic vessel and blood vessel invasion in carcinoma of the lung. Surg Gynecol Obstet 157:185-190, 1983
29. Mountain CE: Revisions in the international system for staging lung cancer. Chest 111:1710-1717, 1997
30. Slebos RJ, Kibbelaar RE, Dalesio O, et al: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561-565, 1990
31. Mitsudomi T, Steinberg SM, Oie H, et al: Ras gene mutations in non-small-cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51:4999-5002, 1991
32. Sugio K, Ishida T, Yokoyama H, et al: ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52:2903-2906, 1992
33. Keohavong P, De Michele MAA, Melacrinos AC, et al: Detection of K-ras mutations in lung carcinomas: Relationship to prognosis. Clin Cancer Res 2:411-418, 1996
34. Resell R, Molina F, Moreno I, et al: Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIa non-small-cell lung cancer. Lung Cancer 12:S59-S70, 1995